Sanofi ends option phase of rare disease partnership with Alnylam
Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2183 entries already.
Entries by Thomas Gabrielczyk
Medigene AG in potential €1bn licence and R&D deal
Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation in the eastern Asian market.
AMR diagnostic specialist Gradientech raise $4.6m
Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
Reaching global markets
Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.
AgomAb Therapeutics bags €21m Series A financing
AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing.
European Biotechnology Guide in its ninth edition
The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Novartis acquires inflammasome blocker company IFM Tre
Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.
EMA recommends bluebird’s ?-thalassemia gene therapy
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
No Games. Just Deals!
As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.
Selvita to spin out cancer business
Krakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.